Exogenous gangliosides - How do they cross the blood-brain barrier and how do they inhibit cell proliferation?

Cara Lynne Schengrund, Christine M. Mummert

    Research output: Contribution to journalArticlepeer-review

    13 Scopus citations

    Abstract

    Gangliosides have been used to treat specific central nervous system lesions and to inhibit proliferation of neuroblastoma cells in vitro. However, the mechanisms by which they (1) cross the blood-brain barrier and (2) inhibit cell proliferation have not been clearly defined. Evidence is presented in support of the hypotheses that (1) serum albumin functions in the transport of gangliosidcs across the blood-brain barrier, and (2) when gangliosides inhibit cell proliferation, they do so by inhibiting the activity of DNA polymerases α and β.

    Original languageEnglish (US)
    Pages (from-to)278-283
    Number of pages6
    JournalAnnals of the New York Academy of Sciences
    Volume845
    DOIs
    StatePublished - 1998

    All Science Journal Classification (ASJC) codes

    • General Neuroscience
    • General Biochemistry, Genetics and Molecular Biology
    • History and Philosophy of Science

    Fingerprint

    Dive into the research topics of 'Exogenous gangliosides - How do they cross the blood-brain barrier and how do they inhibit cell proliferation?'. Together they form a unique fingerprint.

    Cite this